The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 13, 2025
Filed:
May. 17, 2023
Applicant:
Idorsia Pharmaceuticals Ltd, Allschwil, CH;
Inventors:
Martin Bolli, Allschwil, CH;
Markus Von Raumer, Allschwil, CH;
Assignee:
IDORSIA PHARMACEUTICALS LTD, Allschwil, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); A61K 31/4035 (2006.01); A61K 31/41 (2006.01); A61K 31/4418 (2006.01); A61K 31/506 (2006.01); A61K 31/549 (2006.01); A61P 9/12 (2006.01); A61P 13/12 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61K 31/4035 (2013.01); A61K 31/41 (2013.01); A61K 31/4418 (2013.01); A61K 31/506 (2013.01); A61K 31/549 (2013.01); A61P 9/12 (2018.01); A61P 13/12 (2018.01); C07B 2200/13 (2013.01);
Abstract
The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.